June 20, 2024Open Access

Reliability of Magseed® marking before neoadjuvant systemic therapy with subsequent contrast-enhanced mammography in patients with non-palpable breast cancer lesions after treatment: the MAGMA study

Key Points

Key points are not available for this paper at this time.

Abstract

To assess the reliability of excising residual breast cancer lesions after neoadjuvant systemic therapy (NAST) using a previously localized paramagnetic seed (Magseed®) and the subsequent use of contrast-enhanced spectral mammography (CESM) to evaluate response.

Read Full Paperexternally

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Bravo et al. (Thu,) studied this question.

synapsesocial.com/papers/68e64045b6db6435875d1b56 https://doi.org/https://doi.org/10.1007/s10549-024-07407-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Current status of radioactive seed for localization of non palpable breast lesions2009 · 163 citations
2New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,496 citations
3Health at a Glance: Europe 20182018 · 526 citations
4Workflow Considerations for Incorporation of Contrast-Enhanced Spectral Mammography Into a Breast Imaging Practice2018 · 30 citations
5Impact of transition from analog screening mammography to digital screening mammography on screening outcome in The Netherlands: a population-based study2012 · 80 citations

Perguntar à IA

Bookmark

View Full Paper